FDA Brief

Warning letters Drugs

FDA warning letter to

Louisiana State University Health Science Center IRB

MediumIssued Sep 27, 2024Posted Oct 8, 2024Center for Drug Evaluation and Research (CDER)

FDA warns Louisiana State University Health Science Center IRB about missed continuing reviews and unreported study terminations for drug research.

What happened

FDA inspected the LSUHSC IRB from July 17 to July 26, 2023, to check compliance with human-subject protection rules. FDA found the IRB missed required at-least-yearly continuing reviews for multiple drug studies, with approval lapses of up to 78 days; during one lapse, enrollment and protocol deviations occurred. FDA also found the IRB did not have explicit written procedures for reporting suspensions or terminations of approval to FDA and did not report eight administrative closures as terminations.

What FDA found

  1. For multiple protocols, the IRB let required continuing review lapse, including one lapse of 78 days while enrollment and protocol deviations occurred.

    21 CFR 56.109(f)
  2. The IRB's written procedures did not explicitly say how suspensions or terminations of IRB approval would be reported to FDA.

    21 CFR 56.115(a)(6) and 56.108(b)(3)
  3. The IRB did not report eight administrative closures of studies to FDA as terminations of IRB approval.

    21 CFR 56.113 and 56.108(b)(3)

What FDA wants

Within 15 business days of receiving the letter, the IRB should tell FDA in writing what it has done or plans to do to fix the violations and prevent repeat violations. FDA says failure to address the matter adequately may lead to regulatory action.

Who should pay attention

  • IRBs overseeing FDA-regulated clinical trials
  • sponsors relying on academic IRBs
  • research sites enrolling under IRB-approved protocols

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  2. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  3. Naseem A. Jaffrani, M.D.

    FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.

    High risk
  4. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk